UK markets open in 13 minutes

Smith & Nephew plc (SN.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
1,134.50-3.00 (-0.26%)
At close: 05:07PM GMT

Smith & Nephew plc

Building 5
Croxley Park Hatters Lane
Watford WD18 8YE
United Kingdom
44 1923 477 100

IndustryMedical Devices
Full-time employees19,000

Key executives

NameTitlePayExercisedYear born
Dr. Deepak S. Nath Ph.D.CEO & Director4.7MN/A1972
Ms. Anne-Francoise NesmesCFO & Executive Director1.07MN/A1971
Mr. Paul ConnollyPresident of Global OperationsN/AN/A1968
Mr. Andrew SwiftVice President of Investor RelationsN/AN/AN/A
Ms. Helen BarracloughGroup General Counsel & Company SecretaryN/AN/A1980
Ms. Alison ParkesChief Compliance Officer & Compliance APACN/AN/A1973
Mr. Joe MetzgerSenior Vice President of Marketing Services & CommunicationsN/AN/AN/A
Mr. Philip G. CowdyChief Corporate Development & Corporate Affairs OfficerN/AN/A1967
Ms. Elga LohlerChief Human Resources OfficerN/AN/A1968
Mr. Bradley CannonPresident of Global OrthopaedicsN/AN/A1968
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Corporate governance

Smith & Nephew plc’s ISS governance QualityScore as of 1 February 2024 is 4. The pillar scores are Audit: 8; Board: 2; Shareholder rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.